Monday, June 9, 2025

ICU Rashes

 

ICU Rashes: Clues from the Skin When Organs Are Silent

Dr Neeraj Manikath, Claude.ai

Abstract

Background: Cutaneous manifestations in critically ill patients often provide crucial diagnostic information when traditional clinical assessments are limited by sedation, mechanical ventilation, or altered mental status. Early recognition of characteristic rash patterns can expedite diagnosis and treatment of life-threatening conditions.

Objective: To provide a systematic approach to recognizing and interpreting skin manifestations of critical illness, focusing on disseminated intravascular coagulation (DIC), drug-induced eruptions, vasculitis, meningococcemia, and toxic epidermal necrolysis (TEN).

Methods: Comprehensive review of current literature and clinical guidelines for dermatologic manifestations in intensive care settings.

Results: Five key dermatologic patterns emerge as critical diagnostic indicators in the ICU setting, each with distinct morphologic features, distribution patterns, and associated systemic findings that guide immediate therapeutic interventions.

Conclusion: Systematic skin examination in critically ill patients provides invaluable diagnostic information that can significantly impact patient outcomes when organs fail to communicate their distress through conventional means.

Keywords: Critical care dermatology, ICU rashes, DIC, drug eruptions, vasculitis, meningococcemia, toxic epidermal necrolysis

Introduction

The intensive care unit presents a unique clinical environment where patients often cannot communicate their symptoms, and traditional examination techniques may be limited by sedation, mechanical ventilation, or altered consciousness. In this challenging setting, the skin serves as a readily accessible diagnostic window, offering vital clues when other organ systems remain "silent."

Critical care physicians must develop expertise in recognizing cutaneous manifestations that herald life-threatening conditions requiring immediate intervention. The skin, being the largest organ, frequently reflects systemic pathology and can provide the first—and sometimes only—visible sign of conditions such as disseminated intravascular coagulation, severe drug reactions, systemic vasculitis, bacterial sepsis, or impending skin necrosis.

This review focuses on five high-yield dermatologic patterns that every intensivist must recognize: the purpuric patches of DIC, the progressive erythema of drug reactions, the palpable purpura of vasculitis, the rapidly spreading petechiae of meningococcemia, and the ominous blistering of toxic epidermal necrolysis.

The "Big Five" ICU Rashes: Recognition and Response

1. Disseminated Intravascular Coagulation (DIC): The Purple Prophecy

Clinical Pearl: "Purple patches predict poor prognosis" - When you see symmetric purpuric lesions on pressure points in a critically ill patient, think DIC until proven otherwise.

Morphology and Distribution

DIC-related skin manifestations typically present as:

  • Symmetric purpuric patches on pressure-bearing areas (sacrum, heels, elbows)
  • Acral cyanosis affecting fingers and toes
  • Hemorrhagic bullae in advanced cases
  • Widespread petechiae in mucosal areas

The "Fingertip Test"

Clinical Hack: Press on a purpuric lesion - if it doesn't blanch and feels firm, suspect dermal necrosis from microvascular thrombosis characteristic of DIC.

Pathophysiology

The skin manifestations result from:

  • Consumption of clotting factors leading to bleeding
  • Microthrombi formation causing ischemic necrosis
  • Complement activation triggering inflammatory cascades
  • Endothelial dysfunction compromising microcirculation

Laboratory Correlation

  • Prolonged PT/PTT with low platelets
  • Elevated D-dimer and fibrin degradation products
  • Decreased fibrinogen levels
  • Schistocytes on peripheral smear

Management Priorities

  1. Immediate: Address underlying trigger (sepsis, trauma, malignancy)
  2. Supportive: Platelet and plasma transfusions as indicated
  3. Monitoring: Serial coagulation studies and platelet counts
  4. Wound care: Gentle handling of necrotic areas

2. Drug-Induced Skin Reactions: The Therapeutic Traitor

Clinical Pearl: "When in doubt, blame the drug" - In ICU patients receiving multiple medications, always consider drug reaction in any new rash.

Spectrum of Presentations

Maculopapular Drug Eruptions
  • Onset: Typically 7-14 days after drug initiation
  • Morphology: Symmetric erythematous macules and papules
  • Distribution: Trunk-predominant, spreading to extremities
  • Key feature: Spares palms and soles initially
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
  • The "DRESS Code": Delayed onset (2-8 weeks), facial edema, lymphadenopathy, organ involvement
  • Laboratory: Eosinophilia >1000/μL, atypical lymphocytes
  • Organs at risk: Liver, kidneys, lungs, heart
Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN)
  • The "Rule of 10s": <10% body surface area = SJS, >30% = TEN
  • Nikolsky sign positive: Lateral pressure causes epidermis to slide
  • Mucosal involvement: Eyes, mouth, genitals affected

High-Risk Medications in ICU

  1. Antibiotics: Vancomycin, beta-lactams, sulfonamides
  2. Anticonvulsants: Phenytoin, carbamazepine, phenobarbital
  3. Allopurinol: Especially in patients with renal impairment
  4. NSAIDs: Including selective COX-2 inhibitors

The "STOP-SWITCH-STEROID" Approach

  1. STOP: Discontinue suspected offending agent immediately
  2. SWITCH: Use alternative medication if continued therapy needed
  3. STEROID: Consider systemic corticosteroids for severe reactions

3. Vasculitis: The Palpable Purple Clue

Clinical Pearl: "If you can feel it, it's real vasculitis" - Palpable purpura indicates vessel wall inflammation, not just bleeding.

Classification and Recognition

Small Vessel Vasculitis
  • Morphology: Palpable purpura, typically 2-10mm
  • Distribution: Lower extremities, dependent areas
  • Associated features: Urticaria, nodules, ulcerations
Medium Vessel Vasculitis
  • Morphology: Larger purpuric lesions, nodules, ulcers
  • Distribution: Any location, often asymmetric
  • Associated features: Livedo reticularis, digital ischemia

The "Vasculitis Vital Signs"

Always check for:

  • Hypertension: Renal involvement
  • Proteinuria/hematuria: Glomerulonephritis
  • Neurologic deficits: CNS vasculitis
  • Abdominal pain: Mesenteric involvement
  • Pulmonary symptoms: Lung involvement

Laboratory Workup

  • ANCA: c-ANCA (GPA), p-ANCA (MPA, EGPA)
  • Complement: C3, C4 levels
  • Antinuclear antibodies: SLE-associated vasculitis
  • Hepatitis B/C serology: Cryoglobulinemic vasculitis
  • Urinalysis: Active urinary sediment

Biopsy Timing

Critical Decision Point: Biopsy fresh lesions (<24-48 hours old) for optimal histologic yield. Older lesions show nonspecific changes.

4. Meningococcemia: The Race Against Time

Clinical Pearl: "Petechiae that appear while you watch demand immediate action" - Rapidly progressive petechial rash in a febrile patient is meningococcemia until proven otherwise.

Stages of Progression

Stage 1: Early (Hours 0-6)
  • Blanching erythematous macules
  • Often mistaken for viral exanthem
  • Predominantly on trunk and extremities
Stage 2: Intermediate (Hours 6-12)
  • Non-blanching petechiae appear
  • May be sparse initially
  • Check conjunctivae and oral mucosa
Stage 3: Advanced (Hours 12-24)
  • Extensive purpuric lesions
  • Hemorrhagic bullae
  • Areas of skin necrosis

The "Meningococcal March"

  1. Fever and malaise (non-specific)
  2. Petechial rash appears (diagnostic window opens)
  3. Rapid progression (hours, not days)
  4. Shock and organ failure (often irreversible)

Diagnostic Approach

  • Blood cultures: Before antibiotic administration
  • Lumbar puncture: If no contraindications
  • PCR testing: Rapid molecular diagnosis
  • Antigen testing: Urine, serum, CSF

The "Golden Hour" Protocol

  1. Immediate antibiotics: Ceftriaxone 2g IV
  2. Shock management: Aggressive fluid resuscitation
  3. Steroid consideration: Dexamethasone if meningitis suspected
  4. Contact tracing: Public health notification
  5. Prophylaxis: Close contacts need antibiotics

5. Toxic Epidermal Necrolysis (TEN): The Burning Skin Emergency

Clinical Pearl: "When skin comes off like tissue paper, every minute matters" - TEN is a dermatologic emergency requiring immediate specialized care.

Staging and Assessment

Prodromal Phase (1-3 days)
  • Fever, malaise, sore throat
  • Skin tenderness before visible changes
  • Often misdiagnosed as flu-like illness
Acute Phase (Days 1-4)
  • Nikolsky sign: Lateral pressure causes epidermis to detach
  • Target lesions: Atypical targets with dark centers
  • Mucosal involvement: Eyes, mouth, genitals, airways
Detachment Phase (Days 3-5)
  • Body surface area involvement: >30% in TEN
  • Flaccid bullae: Large, easily ruptured
  • Raw, denuded areas: Resembling burns

SCORTEN Scoring System

Prognostic tool assessing:

  • Age >40 years
  • Heart rate >120 bpm
  • Malignancy
  • Body surface area >10%
  • Serum urea >10 mmol/L
  • Bicarbonate <20 mmol/L
  • Blood glucose >14 mmol/L

Score interpretation: Each point increases mortality risk by approximately 10-15%.

Management Principles

Immediate Actions
  1. Stop offending drug: Review all medications
  2. Supportive care: Like severe burn management
  3. Fluid/electrolyte balance: Large surface losses
  4. Infection prevention: Sterile technique essential
  5. Pain management: Often severe and underestimated
Specialized Interventions
  • IVIG consideration: 2-3 g/kg over 3-5 days
  • Ophthalmologic care: Prevent ocular complications
  • Wound care: Specialized dressings, avoid adhesives
  • Nutritional support: High protein, calorie requirements

Systematic Approach to ICU Rash Evaluation

The "RASH" Framework

Recognize the Pattern

  • Morphology: Macules, papules, purpura, bullae
  • Distribution: Symmetric vs. asymmetric, central vs. peripheral
  • Evolution: Static vs. progressive

Assess the Timeline

  • Acute onset: <24 hours (meningococcemia, drug reaction)
  • Subacute: Days to weeks (vasculitis, DRESS)
  • Chronic: Weeks to months (systemic disease)

Search for Associated Features

  • Fever pattern: Continuous vs. intermittent
  • Organ involvement: Renal, hepatic, pulmonary, neurologic
  • Laboratory abnormalities: Coagulation, inflammatory markers

Handle with Urgency

  • Life-threatening: TEN, meningococcemia, severe drug reactions
  • Organ-threatening: Vasculitis with renal involvement
  • Function-threatening: Extensive skin necrosis

Clinical Pearls and Memory Aids

The "5 P's of Purpura"

  1. Platelets: Low count (ITP, TTP, DIC)
  2. Pressure: Dependent distribution (cardiac failure)
  3. Palpable: Vasculitis (inflammation in vessel walls)
  4. Pattern: Distribution suggests etiology
  5. Progression: Rate indicates urgency

The "DRESS Rehearsal"

Delayed onset (2-8 weeks)
Rash with facial edema
Eosinophilia >1000/μL
Systemic organ involvement
Severe and potentially fatal

The "TEN Commandments"

  1. Stop the offending drug immediately
  2. Supportive care like burn management
  3. Sterile technique for all procedures
  4. Specialist consultation (dermatology, ophthalmology)
  5. SCORTEN score for prognosis
  6. Surveillance for complications
  7. Symptomatic pain management
  8. Supplement nutrition aggressively
  9. Systemic treatments (IVIG consideration)
  10. Save the skin with appropriate dressings

Diagnostic Algorithms and Decision Trees

Initial Rash Assessment in ICU

Critically ill patient with new rash
                    ↓
            Assess morphology
                    ↓
    ┌──────────────┼──────────────┐
    ↓              ↓              ↓
Petechiae/     Maculopapular   Vesicles/
Purpura         Eruption       Bullae
    ↓              ↓              ↓
Check CBC,    Review drugs,   Check for
Coags, LDH    Check eos,     Nikolsky sign,
    ↓         organ function  mucosal involvement
    ↓              ↓              ↓
Consider:     Consider:      Consider:
• DIC         • Drug reaction • TEN/SJS
• Vasculitis  • DRESS        • Bullous disease
• Meningococcal• Viral        • Drug reaction
• TTP/HUS      exanthem

Prevention and Risk Stratification

High-Risk Patients

  • Immunocompromised: Transplant recipients, chemotherapy patients
  • Multiple medications: Polypharmacy increases drug reaction risk
  • Renal/hepatic impairment: Altered drug metabolism
  • Previous drug reactions: Increased susceptibility
  • Genetic factors: HLA-B5801 (allopurinol), HLA-B1502 (carbamazepine)

Prevention Strategies

  1. Medication reconciliation: Regular review and deprescribing
  2. Allergy documentation: Clear, specific allergy history
  3. Pharmacogenetic testing: For high-risk medications when available
  4. Early recognition training: Staff education on warning signs
  5. Rapid response protocols: Clear escalation pathways

Conclusions and Future Directions

The skin serves as a critical diagnostic organ in the intensive care setting, often providing the first and most accessible clues to life-threatening systemic conditions. Recognition of the "Big Five" ICU rashes—DIC-related purpura, drug-induced eruptions, vasculitic lesions, meningococcal petechiae, and toxic epidermal necrolysis—can significantly impact patient outcomes through early diagnosis and intervention.

Future research directions include development of artificial intelligence-assisted diagnostic tools for rash recognition, point-of-care biomarkers for rapid differentiation of rash etiologies, and personalized medicine approaches incorporating pharmacogenetic testing to prevent severe drug reactions.

The key to success lies in systematic approach, high index of suspicion, and multidisciplinary collaboration between intensivists, dermatologists, and other specialists. Remember: when organs are silent, the skin often speaks loudest.

Key Teaching Points for Residents

  1. Daily skin checks: Incorporate systematic skin examination into daily ICU rounds
  2. Pattern recognition: Learn the classic distributions and morphologies
  3. Temporal relationships: Always correlate rash onset with medication timing
  4. Biopsy timing: Fresh lesions provide better diagnostic yield
  5. Multidisciplinary approach: Early dermatology consultation for complex cases
  6. Documentation: Photograph rashes when possible for progression monitoring
  7. Family communication: Skin changes are often first visible sign families notice

Corresponding Author: [Author information would be inserted here]
Conflicts of Interest: None declared
Funding: No external funding received

References

  1. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol. 2013;68(5):693.e1-693.e14. doi:10.1016/j.jaad.2013.01.033

  2. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149-153. doi:10.1046/j.1523-1747.2000.00061.x

  3. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi:10.1002/art.37715

  4. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 2009;145(1):24-33. doi:10.1111/j.1365-2141.2009.07600.x

  5. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196-2210. doi:10.1016/S0140-6736(07)61016-2

  6. Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013;133(5):1197-1204. doi:10.1038/jid.2012.510

  7. Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011;7(6):803-813. doi:10.1586/eci.11.66

  8. Carlson JA, Ng BT, Chen KR. Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol. 2005;27(6):504-528. doi:10.1097/01.dad.0000187909.42279.c8

  9. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272-1285. doi:10.1056/NEJM199411103311906

  10. Khanna D, Matteson EL, Furst DE, et al. Longterm safety and efficacy of adalimumab in patients with rheumatoid arthritis: analysis of Indian patients from global clinical trials. J Assoc Physicians India. 2014;62(4):28-34.

  11. Pichler WJ, Naisbitt DJ, Park BK. Immune pathomechanism of drug hypersensitivity reactions. J Allergy Clin Immunol. 2011;127(3 Suppl):S74-S81. doi:10.1016/j.jaci.2010.11.048

  12. Brandtzaeg P, van Deuren M. Classification and pathogenesis of meningococcal infections. Methods Mol Biol. 2012;799:21-35. doi:10.1007/978-1-61779-346-2_2

  13. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol. 2006;6(4):543-549. doi:10.1016/j.intimp.2005.11.013

  14. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-1026. doi:10.1111/jth.14810

  15. Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222-227. doi:10.1136/ard.2006.054593

  16. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol. 2007;156(5):1083-1084. doi:10.1111/j.1365-2133.2007.07808.x

  17. Creamer D, Walsh SA, Dziewulski P, et al. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016;174(6):1194-1227. doi:10.1111/bjd.14530

  18. van Deuren M, Brandtzaeg P, van der Meer JW. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev. 2000;13(1):144-166. doi:10.1128/CMR.13.1.144-166.2000

  19. Gando S, Iba T, Eguchi Y, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34(3):625-631. doi:10.1097/01.CCM.0000202209.42491.38

  20. Sunderkötter CH, Zelger B, Chen KR, et al. Nomenclature of cutaneous vasculitis: dermatologic addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheumatol. 2018;70(2):171-184. doi:10.1002/art.40375

at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Hemato-Critical Syndromes

  The "Hemato-Critical" Syndromes – 5 Emergencies You Must Not Miss: A Critical Care Perspective Dr Neeraj Manikath, Claude.ai Abs...

  • Refractory Hypotension in the Intensive Care Unit
      Refractory Hypotension in the Intensive Care Unit: A Comprehensive Review Dr Neeraj Manikath ,Claude.ai Abstract Refractory hypotension re...
  • Day to day rounds in ICU
      Practical Approaches to Day-to-Day Monitoring in the ICU: A Comprehensive Guide for Critical Care Practitioners  Dr Neeraj Manikath, Claud...
  • Focused Examination in 5 Minutes
      Focused Examination in 5 Minutes Dr Neeraj manikath, Claude.ai Introduction The outpatient department presents a unique challenge: condu...